Cited by 109vaccines and immunoinformatics approachesBiosimilars and Bioanalytical MethodsMonoclonal and Polyclonal Antibodies Research

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates

DEGROOT, A, MCMURRY, J, MOISE, L·2008·Current Opinion in Pharmacology

DOI 10.1016/j.coph.2008.08.002

Open this paper in CoChat — free account

Abstract

Immunogenicity can be a major obstacle to successful protein drug therapy. Antidrug antibodies may neutralize therapeutic function, influence pharmacokinetics and, in some cases, lead to severe adverse effects. These effects depend on factors including dose, regimen, delivery route and contaminants, among others. Importantly, immunogenicity is a consideration that is better addressed during preclinical development before complications arise in clinical trials or following licensure. This article will address the development and application of computational tools for immunogenicity assessment of protein therapeutics, and validation of those predictions using peripheral blood from exposed subjects or alternative in vivo methods.

Integrity signals

Registry

Crossref · 10.1016/j.coph.2008.08.002

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

NOD/SCID/γcnull mouse: an excellent recipient mouse model for engraftment of human cells
Ito, M., Hiramatsu, H., Kobayashi, K., Suzue, K., Kawahata, M., Hioki, K., Ueyama, Y., Koyanagi, Y., Sugamura, K., Tsuji, K., et al. (2002) · Blood · doi:10.1182/blood-2001-12-0207 · Cited by 1,483
Natural versus adaptive regulatory T cells
Bluestone, J. A., & Abbas, A. K. (2003) · Nature reviews. Immunology · doi:10.1038/nri1032 · Cited by 1,319
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
Casadevall, N., Nataf, J., Viron, B. M., Kolta, A. M., Kiladjian, J., Martin-Dupont, P., Michaud, P. A., Papo, T., Ugo, V., Teyssandier, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011931 · Cited by 1,244
Multiple defects in innate and adaptive immunologic function in NOD/LtSz- scid mice.
Shultz, L. D., Schweitzer, P. A., Christianson, S. W., Gott, B., Schweitzer, I. B., Tennent, B. J., McKenna, S., Mobraaten, L. E., Rajan, T. V., Greiner, D. L., et al. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.1.180 · Cited by 1,224
Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice
Traggiai, E., Chicha, L., Mazzucchelli, L., Bronz, L., Piffaretti, J.-C., Lanzavecchia, A., & Manz, M. G. (2004) · Science · doi:10.1126/science.1093933 · Cited by 989
Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice
Ishikawa, F., Yasukawa, M., Lyons, B. L., Yoshida, S., Miyamoto, T., Yoshimoto, G., Watanabe, T., Akashi, K., Shultz, L. D., & Harada, M. (2005) · Blood · doi:10.1182/blood-2005-02-0516 · Cited by 933
Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires
Southwood, S., Sidney, J., Kondo, A., del Guercio, M., Appella, E., Hoffman, S. L., Kubo, R. T., Chesnut, R. W., Grey, H. M., & Sette, A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3363 · Cited by 665
Immunogenicity of protein therapeutics
Groot, A. S. D., & Scott, D. W. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.07.011 · Cited by 544
Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”
Groot, A. S. D., Moise, L., McMurry, J. A., Wambre, E. R., Overtvelt, L. V., Moingeon, P. E., Scott, D. W., & Martin, W. D. (2008) · Blood · doi:10.1182/blood-2008-02-138073 · Cited by 392
Self-citation
A Novel Mechanism of Action for Anti-Thymocyte Globulin
Lopez, M., Clarkson, M. R., Albin, M., Sayegh, M. H., & Najafian, N. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050422 · Cited by 365
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products.
Koren, E., Smith, H. W., Shores, E., Shankar, G., Finco-Kent, D., Rup, B., Barrett, Y., Devanarayan, V., Gorovits, B., Gupta, S., et al. (2008) · JIM - Journal of Immunological Methods · doi:10.1016/j.jim.2008.01.001 · Cited by 332
CEP: a conformational epitope prediction server
Kulkarni‐Kale, U., Bhosle, S. G., & Kolaskar, A. S. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki460 · Cited by 299
Viral immune evasion: a masterpiece of evolution
Vossen, M. T., Westerhout, E. M., Söderberg-Nauclér, C., & Wiertz, E. (2002) · Immunogenetics · doi:10.1007/s00251-002-0493-1 · Cited by 279
Immune Responses to Therapeutic Proteins in Humans - Clinical Significance, Assessment and Prediction
Koren, E., Zuckerman, L., & Mire‐Sluis, A. R. (2002) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023378175 · Cited by 267
Creation of “Humanized” Mice to Study Human Immunity
Pearson, T., Greiner, D. L., & Shultz, L. D. (2008) · Current Protocols in Immunology · doi:10.1002/0471142735.im1521s81 · Cited by 214
Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide
Steere, A., Klitz, W., Drouin, E. E., Falk, B., Kwok, W., Nepom, G., & Lee, A. B.-L. (2006) · Journal of Experimental Medicine · doi:10.1084/jem.20052471 · Cited by 207
Detection of GAD65-Specific T-Cells by Major Histocompatibility Complex Class II Tetramers in Type 1 Diabetic Patients and At-Risk Subjects
Reijonen, H., Novak, E. J., Kochik, S. A., Heninger, A., Liu, A. W., Kwok, W. W., & Nepom, G. T. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1375 · Cited by 201
Antibody Response to Aggregated Human Interferon Alpha2b in Wild-type and Transgenic Immune Tolerant Mice Depends on Type and Level of Aggregation
Hermeling, S., Schellekens, H., Maas, C., Gebbink, M. F. B. G., Crommelin, D. J. A., & Jiskoot, W. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20599 · Cited by 187
CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1.
Shirai, M., Arichi, T., Nishioka, M., Nomura, T., Ikeda, K., Kawanishi, K., Engelhard, V. H., Feinstone, S. M., & Berzofsky, J. A. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.6.2733 · Cited by 165
Utilization of MHC Class I Transgenic Mice for Development of Minigene DNA Vaccines Encoding Multiple HLA-Restricted CTL Epitopes
Ishioka, G. Y., Fikes, J. D., Hermanson, G., Livingston, B. D., Crimi, C., Qin, M., del Guercio, M., Oseroff, C., Dahlberg, C. M., Alexander, J., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.7.3915 · Cited by 164
NOD/LtSz- Rag1 null Mice: An Immunodeficient and Radioresistant Model for Engraftment of Human Hematolymphoid Cells, HIV Infection, and Adoptive Transfer of NOD Mouse Diabetogenic T Cells
Shultz, L. D., Lang, P. A., Christianson, S. W., Gott, B., Lyons, B. L., Umeda, S., Leiter, E. H., Hesselton, R., Wagar, E. J., Leif, J., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2496 · Cited by 160
Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines
Livingston, B. D., Newman, M. J., Crimi, C., McKinney, D. M., Chesnut, R. W., & Sette, A. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00233-x · Cited by 155
Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences
Meister, G. T. (1995) · Vaccine · doi:10.1016/0264-410x(94)00014-e · Cited by 155
Immunomics: discovering new targets for vaccines and therapeutics
Groot, A. S. D. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03720-7 · Cited by 153
Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein
Koren, E., Groot, A. S. D., Jawa, V., Beck, K. D., Boone, T., Rivera, D., Li, L., Mytych, D. T., Koscec, M., Weeraratne, D. K., et al. (2007) · Clinical Immunology · doi:10.1016/j.clim.2007.03.544 · Cited by 143
HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA-DRB1*0301 (DR3) gene.
Kong, Y. C., Lomo, L. C., Motte, R. W., Giraldo, A. A., Baisch, J., Strauß, G., Hämmerling, G. J., & David, C. S. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.3.1167 · Cited by 137
Safety and Immunogenicity of Tyrosinase DNA Vaccines in Patients with Melanoma
Wolchok, J. D., Yuan, J. D., Houghton, A. N., Gallardo, H. F., Rasalan, T. S., Wang, J., Zhang, Y., Ranganathan, R., Chapman, P. B., Krown, S. E., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300290 · Cited by 107
Rational Design of a Multiepitope Vaccine Encoding T-Lymphocyte Epitopes for Treatment of Chronic Hepatitis B Virus Infections
Depla, E., der Aa, A. V., Livingston, B. D., Crimi, C., Allosery, K., Brabandere, V. D., Krakover, J. D., Murthy, S., Huang, M. T. F., Power, S., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01505-07 · Cited by 106
Untitled work
(2007) · PubMed · Cited by 100
Self-citation
Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII
Reding, M. T., Okita, D. K., Diethelm-Okita, B. M., Anderson, T. A., & Conti‐Fine, B. M. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00251.x · Cited by 99
From genome to vaccine—new immunoinformatics tools for vaccine design
Groot, A. S. D., & Berzofsky, J. A. (2004) · Methods · doi:10.1016/j.ymeth.2004.06.004 · Cited by 93
3D‐Epitope‐Explorer (3DEX): Localization of conformational epitopes within three‐dimensional structures of proteins
Schreiber, A. W., Humbert, M., Benz, A., & Dietrich, U. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20229 · Cited by 92
A systematic bioinformatics approach for selection of epitope-based vaccine targets
Khan, A. M., Miotto, O., Heiny, A. T., Salmon, J., Srinivasan, K. N., Nascimento, E. J. M., Marques, E. T. A., Brusić, V., Tan, T. W., & August, J. T. (2006) · Cellular Immunology · doi:10.1016/j.cellimm.2007.02.005 · Cited by 90
High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection
Ahlers, J. D., Belyakov, I. M., Thomas, E. K., & Berzofsky, J. A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13463 · Cited by 87
The Mapping and Reconstitution of a Conformational Discontinuous B-cell Epitope of HIV-1
Enshell‐Seijffers, D., Denisov, D. A., Groisman, B., Smelyanski, L., Meyuhas, R., Gross, G., Denisova, G. F., & Gershoni, J. M. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.09.002 · Cited by 85
The genetic basis of autoantibody production
Reveille, J. D. (2005) · Autoimmunity Reviews · doi:10.1016/j.autrev.2005.10.012 · Cited by 84
Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes
McMurry, J. A., Sbai, H., Gennaro, M. L., Carter, E. J., Martin, W. D., & Groot, A. S. D. (2004) · Tuberculosis · doi:10.1016/j.tube.2004.09.005 · Cited by 83
Self-citation
Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice
Man, S., Newberg, M. H., Crotzer, V. L., Luckey, C. J., Williams, N. S., Chen, Y., Huczko, E. L., Ridge, J. P., & Engelhard, V. H. (1995) · International Immunology · doi:10.1093/intimm/7.4.597 · Cited by 79
Enumerating Antigen-Specific T-Cell Responses in Peripheral Blood
Hobeika, A. C., Morse, M. A., Osada, T., Ghanayem, M., Niedzwiecki, D., Barrier, R. C., Lyerly, H. K., & Clay, T. M. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200501000-00008 · Cited by 72
Reduced Susceptibility of Recombinant Polyclonal Antibodies to Inhibitory Anti-Variable Domain Antibody Responses
Klitgaard, J. L., Coljee, V. W., Andersen, P. S., Rasmussen, L. K., Nielsen, L. S., Haurum, J., & Bregenholt, S. (2006) · Journal of Immunology · doi:10.4049/jimmunol.177.6.3782 · Cited by 71
Development of a Maturing T-Cell-Mediated Immune Response in Patients with Idiopathic Parkinson’s Disease Receiving r-metHuGDNF Via Continuous Intraputaminal Infusion
Tatarewicz, S. M., Wei, X. L., Gupta, S., Masterman, D. M., Swanson, S. J., & Moxness, M. S. (2007) · Journal of Clinical Immunology · doi:10.1007/s10875-007-9117-8 · Cited by 68
Naive and memory B cells in T-cell-dependent and T-independent responses
Zubler, R. H. (2001) · Springer Seminars in Immunopathology · doi:10.1007/s281-001-8167-7 · Cited by 64
HLA-DR4 (DRB1*0401) Transgenic Mice Expressing an Altered CD4-Binding Site: Specificity and Magnitude of DR4-Restricted T Cell Response
Pan, S., Trejo, T., Hansen, J., Smart, M. K., & David, C. S. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2925 · Cited by 55
The structural requirements for class II (I‐Ad)‐restricted T cell recognition of influenza hemagglutinin: B cell epitopes define T cell epitopes
Graham, C. M., Barnett, B. C., Hartlmayr, I., Burt, D. S., Faulkes, R. A., Skehel, J. J., & Thomas, D. B. (1989) · European Journal of Immunology · doi:10.1002/eji.1830190317 · Cited by 51
Thyrotropin Receptor Epitopes and Their Relation to Histocompatibility Leukocyte Antigen-DR Molecules in Graves’ Disease
Inaba, H., Martin, W. D., Groot, A. S. D., Qin, S., & DeGroot, L. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2537 · Cited by 48
A Comparison of Standard Immunogenicity Assays for Monitoring HIV Type 1 gag-Specific T Cell Responses in Ad5 HIV Type 1 gag Vaccinated Human Subjects
Tobery, T. W., Dubey, S. A., Anderson, K., Freed, D. C., Cox, K. S., Lin, J., Prokop, M. T., Sykes, K. J., Mogg, R., Mehrotra, D. V., et al. (2006) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2006.22.1081 · Cited by 39
Hotspot Hunter: a computational system for large-scale screening and selection of candidate immunological hotspots in pathogen proteomes
Zhang, G., Khan, A. M., Kellathur, S. N., Heiny, A. T., Lee, K. X., Kwoh, C. K., August, J. T., & Brusić, V. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-s1-s19 · Cited by 34
Immunogenicity of protein antigens : repertoire and regulation
Sercarz, E. E., & Berzofsky, J. A. (1987) · Medical Entomology and Zoology · Cited by 32
A repetitive sequence of Epstein–Barr virus nuclear antigen 6 comprises overlapping T cell epitopes which induce HLA-DR-restricted CD4+ T lymphocytes
Rajnavölgyi, É., Nagy, N., Thuresson, B., Dosztányi, Z., Simon, Á., Simon, I., Karr, R. W., Ernberg, I., Klein, E., & Falk, K. I. (2000) · International Immunology · doi:10.1093/intimm/12.3.281 · Cited by 26
The organization of human leucocyte antigen class I epitopes in HIV genome products: implications for HIV evolution and vaccine design
Zhang, C., Cornette, J. L., Berzofsky, J. A., & DeLisi, C. (1997) · Vaccine · doi:10.1016/s0264-410x(97)00040-6 · Cited by 24
DNA Immunization of HLA Transgenic Mice with a Plasmid Expressing Mycobacterial Heat Shock Protein 65 Results in HLA Class I- and II-Restricted T Cell Responses That Can Be Augmented by Cytokines
Charo, J., Sundbäck, M., Geluk, A., Ottenhoff, T. H. M., & Kiessling, R. W. (2001) · Human Gene Therapy · doi:10.1089/104303401750476285 · Cited by 23
Bioinformatics for study of autoimmunity
Petrovsky, N., & Brusić, V. (2006) · Autoimmunity · doi:10.1080/08916930601062437 · Cited by 22
Modelling the immunogenicity of therapeutic proteins using T cell epitope mapping.
Groot, A. S. D., Rayner, J., & Wj, M. (2003) · PubMed · Cited by 17
Application of HLA Class II Transgenic Mice to Study Autoimmune Regulation
Kong, Y.-C. M., Flynn, J. C., Banga, J. P., & David, C. S. (2007) · Thyroid · doi:10.1089/thy.2007.0196 · Cited by 16
Peptide-binding assays and HLA II transgenic Aβ° mice are consistent and complementary tools for identifying HLA II-restricted peptides
Depil, S., Angyalosi, G., Moralès, O., Delacre, M., Delhem, N., François, V., Georges, B., Hammer, J., Maillère, B., Auriault, C., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.11.048 · Cited by 12

Sorted by citations

Stability of Protein Pharmaceuticals: An Update
Manning, M. C., Chou, D. K., Murphy, B. M., Payne, R. W., & Katayama, D. S. (2010) · Pharmaceutical Research · doi:10.1007/s11095-009-0045-6 · Cited by 1,140
The immunogenicity of humanized and fully human antibodies
Harding, F., Stickler, M. M., Razo, J., & DuBridge, R. B. (2010) · mAbs · doi:10.4161/mabs.2.3.11641 · Cited by 743
Immunogenicity of Therapeutic Protein Aggregates
Moussa, E. M., Panchal, J. P., Moorthy, B. S., Blum, J. S., Joubert, M. K., Narhi, L. O., & Topp, E. M. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.002 · Cited by 525
Monoclonal antibody therapeutics: history and future
Buss, N. A. P. S., Henderson, S. J., McFarlane, M., Shenton, J. M., & de Haan, L. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.08.001 · Cited by 480
Therapeutic Proteins
Dimitrov, D. S. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-921-1_1 · Cited by 384

See all 109

Authors: DEGROOT, A., MCMURRY, J., & MOISE, L.
Affiliations: University of Rhode Island (US)
Corresponding author: DEGROOT, A
MOISE, L
ORCID: MCMURRY, J
MOISE, L
Venue: Current Opinion in Pharmacology
Publisher: Elsevier BV
Published: 2008-10
Volume: 8
Issue: 5
Pages: 620-626
ISSN: 1471-4892 (ISSN-L)
DOI: 10.1016/j.coph.2008.08.002
OpenAlex: W2092720388
Cited by: 109
References: 55
Citations by year: 2026: 4 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 7 · 2020: 8 · 2019: 5 · 2018: 10 · 2017: 5 · 2016: 2 · 2015: 5 · 2014: 4 · 2013: 6 · 2012: 14
FWCI: 3.84
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Current Opinion in Pharmacology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords: immunogenicity prediction, therapeutic proteins, antidrug antibodies, in silico prediction tools, preclinical drug development, pharmacokinetics, adverse drug reactions, neutralizing antibodies
MeSH terms: Animals, Epitopes, B-Lymphocytes, Computer Simulation, Drug Evaluation, Preclinical, Humans, Mice, Transgenic, Recombinant Proteins, T-Lymphocytes, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks